DK2729123T3 - Cannabinoidreceptorbindende midler samt sammensætninger og fremgangsmåder - Google Patents

Cannabinoidreceptorbindende midler samt sammensætninger og fremgangsmåder Download PDF

Info

Publication number
DK2729123T3
DK2729123T3 DK12808095.9T DK12808095T DK2729123T3 DK 2729123 T3 DK2729123 T3 DK 2729123T3 DK 12808095 T DK12808095 T DK 12808095T DK 2729123 T3 DK2729123 T3 DK 2729123T3
Authority
DK
Denmark
Prior art keywords
cannabinoid receptor
composition
receptor binding
binding agent
cannabinoid
Prior art date
Application number
DK12808095.9T
Other languages
English (en)
Inventor
Jonathan Bevier
Original Assignee
Patchtek Inc
Jonathan Bevier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patchtek Inc, Jonathan Bevier filed Critical Patchtek Inc
Application granted granted Critical
Publication of DK2729123T3 publication Critical patent/DK2729123T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ceramic Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Claims (15)

1. Sammensætning, der omfatter: a. cannabinoidreceptorbindende midler, der er til stede ved ca. 1 til ca. 55 vægt-% af sammensætningen, hvor de cannabinoidreceptorbindende midler er udvalgt fra gruppen, der består af en cannabinoidreceptor-agonist, en cannabinoidreceptor-antagonist, en kemisk modificeret cannabinoidreceptor-agonist og en kemisk modificeret cannabinoidreceptor-antagonist; og b. partikler, der er bundet til de cannabinoidreceptorbindende midler, hvor partiklerne er til stede ved ca. 75 vægt-% af sammensætningen eller mindre, og hvor partiklerne i deres største dimensioner er mindre end ca. 1000 nanometer.
2. Sammensætning ifølge krav 1, hvor sammensætningen omfatter ca. 15 til ca. 40 vægt-% af de cannabinoidreceptorbindende midler.
3. Sammensætning ifølge krav 1 eller 2, hvor de cannabinoidreceptorbindende midler er fytocannabinoider, der er til stede ved ca. 30 til ca. 40 vægt-% af sammensætningen.
4. Sammensætning ifølge krav 1 eller 2, hvor de cannabinoidreceptorbindende midler er syntetiske cannabinoider, der er til stede ved ca. 10 vægt-% af sammensætningen eller mindre.
5. Sammensætning ifølge et hvilket som helst af kravene 1 til 4, hvor partiklerne er nanokrystallinsk cellulose, der er til stede ved ca. 5 til ca. 40 vægt-% af sammensætningen, og hvor partiklerne i deres største dimension er mindre end ca. 1000 nanometer.
6. Sammensætning ifølge et hvilket som helst af kravene 1 til 5, der yderligere omfatter et plaster til fremføring af sammensætningen til et berørt område.
7. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, der yderligere omfatter et substrat, der er afledt fra en ikke fast sammensætning, der størkner, når den udsættes for et egnet middel, der er udvalgt fra gruppen, der består af et lys, en temperatur og et kemisk aktiveringsmiddel.
8. Sammensætning ifølge et hvilket som helst af kravene 1 til 7, der yderligere omfatter en vesikel til indkapsling af de cannabinoidreceptorbindende midler og partikler til modificering af en egenskab for sammensætningen, hvilken vesikel er udvalgt fra gruppen, der består af liposomer, ethosomer, niosomer og transferosomer.
9. Sammensætning ifølge et hvilket som helst af kravene 1 til 8, hvor partiklerne yderligere omfatter stoffer, der er udvalgt fra gruppen, der består af et metal, en polymer, et lipid og en magnet til modificering af en egenskab for sammensætningen.
10. Sammensætning ifølge et hvilket som helst af kravene 1 til 9, hvor partiklen er funktionaliseret med en del, hvilken del omfatter: a. en forankringsgruppe, der er udvalgt fra gruppen, der består af trialkoxysilaner, phosphonater, sulfonater og bidentatligander, b. en spacer, der er bundet til forankringsgruppen, og c. en funktionel gruppe, der er bundet til forankringsgruppen via spaceren.
11. Sammensætning ifølge krav 10, hvor partiklen omfatter en coating, der er udvalgt fra gruppen, der består af albumin og silikone.
12. Sammensætning, der omfatter et cannabinoidreceptorbindende middel, der er bundet til en partikel, hvor partiklen i dens største dimension er mindre end ca. 1000 nanometer, til anvendelse til behandling af en hudtilstand hos en patient, der har behov derfor, hvor behandlingen omfatter påføring på et berørt område af en terapeutisk effektiv mængde af sammensætningen.
13. Sammensætning ifølge krav 12, hvor det cannabinoidreceptorbindende middel er til stede ved ca. 1 til ca. 55 vægt-% af sammensætningen.
14. Sammensætning ifølge krav 12 eller 13, hvor partiklen er en nanokrystallinsk cellulose, der er til stede ved ca. 75 vægt-% af sammensætningen eller mindre.
15. Sammensætning ifølge krav 12 eller 13, hvor partiklen er en nanokrystallinsk cellulose, der er til stede ved ca. 5 til ca. 40 vægt-% af sammensætningen, og det cannabinoidreceptorbindende middel er til stede ved ca. 15 til ca. 40 vægt-% af sammensætningen.
DK12808095.9T 2011-07-05 2012-07-05 Cannabinoidreceptorbindende midler samt sammensætninger og fremgangsmåder DK2729123T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504655P 2011-07-05 2011-07-05
US13/541,400 US8758826B2 (en) 2011-07-05 2012-07-03 Cannabinoid receptor binding agents, compositions, and methods
PCT/US2012/045613 WO2013006729A2 (en) 2011-07-05 2012-07-05 Cannabinoid receptor binding agents, compositions and methods

Publications (1)

Publication Number Publication Date
DK2729123T3 true DK2729123T3 (da) 2016-01-11

Family

ID=47437703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12808095.9T DK2729123T3 (da) 2011-07-05 2012-07-05 Cannabinoidreceptorbindende midler samt sammensætninger og fremgangsmåder

Country Status (9)

Country Link
US (2) US8758826B2 (da)
EP (2) EP2995302A1 (da)
JP (1) JP2014520817A (da)
KR (1) KR20140065387A (da)
CN (1) CN103796637A (da)
CA (1) CA2840907C (da)
DK (1) DK2729123T3 (da)
MX (1) MX340962B (da)
WO (1) WO2013006729A2 (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN06581A (da) 2010-03-17 2015-10-23 Novaliq Gmbh
KR101790388B1 (ko) 2011-05-25 2017-10-25 노바리크 게엠베하 부분불소화된 알칸에 기초된 국소 제약학적 조성물
FI130619B (en) 2011-11-15 2023-12-15 Upm Kymmene Corp Matrix for controlled release of bioactive substances
WO2013106822A1 (en) 2012-01-12 2013-07-18 Johnson Jed K Nanofiber scaffolds for biological structures
MX2014013826A (es) 2012-05-16 2018-04-24 Singh Mewa Composiciones farmaceuticas para la entrega de farmacos sustancialmente solubles en agua.
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
BR112015004997B1 (pt) 2012-09-12 2022-09-13 Novaliq Gmbh Composições oftálmicas contendo misturas de alcanos semifluorados
EP3730929A1 (en) 2013-08-19 2020-10-28 University Of Houston Phosphorescent reporters
WO2015048508A1 (en) 2013-09-26 2015-04-02 Sekura Ronald D Topical treatments incorporating cannabis sp. derived botanical drug product
CN106232626B (zh) 2014-03-27 2022-05-03 鸟石生物公司 结合人大麻素1(cb1)受体的抗体
WO2015171445A1 (en) * 2014-05-06 2015-11-12 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US9436682B2 (en) * 2014-06-24 2016-09-06 Google Inc. Techniques for machine language translation of text from an image based on non-textual context information from the image
US9907823B1 (en) 2014-11-07 2018-03-06 Eric H. Kuhrts Water-soluble phytocannabinoid formulations
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2015385825A1 (en) 2015-03-10 2017-10-05 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
US10456435B2 (en) 2015-07-15 2019-10-29 Christopher A. MCELVANY Topical antiviral formulations and methods of using the same
CA2995418A1 (en) * 2015-08-11 2017-02-16 KannaInnovations LLC Topical compositions comprising hydroxy acids and cannabinoids for skin care
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
WO2017058771A1 (en) 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) recetor
CN113662928A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
EP3370788A4 (en) 2015-11-02 2019-07-31 Nanofiber Solutions, LLC ELECTRO-spun fibers with contrast agents and method for producing same
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CN109803650A (zh) 2016-09-28 2019-05-24 诺瓦利克有限责任公司 包含大麻素受体结合配体的组合物
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2018144637A1 (en) * 2017-02-01 2018-08-09 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
US10898608B2 (en) 2017-02-02 2021-01-26 Nanofiber Solutions, Llc Methods of improving bone-soft tissue healing using electrospun fibers
AU2018221881B2 (en) * 2017-02-15 2023-09-14 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of acne
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
MX2019013327A (es) * 2017-05-08 2020-07-27 Inmed Pharmaceuticals Inc Formulación para administración ocular de fármacos.
CN110650734A (zh) 2017-05-12 2020-01-03 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
US20180333565A1 (en) * 2017-05-22 2018-11-22 Moshe Ein-Gal Pressure wave drug delivery
EP3630067A4 (en) * 2017-05-26 2021-08-11 Altum Pharmaceuticals Inc. BIPHASIC CANNABINOID ADMINISTRATION
DK3641753T3 (da) * 2017-06-19 2022-12-12 Univ Syddansk Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner
US11318179B2 (en) 2017-06-20 2022-05-03 Jessica Kado Topical formulation for binding to dermatological cannabinoid receptors
US10543176B2 (en) * 2017-06-20 2020-01-28 Jessica Kado Topical formulation for binding to dermatological cannabinoid receptors
US20190054036A1 (en) * 2017-08-17 2019-02-21 Nanofiber Solutions, Inc. Electrospun fibers having a pharmaceutical and methods of making and using the same
US11484510B2 (en) * 2017-08-28 2022-11-01 Apirx Pharmaceutical Usa, Llc Method to treat vitiligo
WO2019063551A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES
CA3076567A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh Ophthalmic compositions
AU2018352039B2 (en) * 2017-10-18 2024-03-14 Mor Research Applications Ltd. Cannabidiol and chitosan compositions and methods of using the same
CA3086357A1 (en) * 2017-12-18 2019-06-27 Nanostrips, Inc. Transmucosal delivery device and method of manufacturing same
CA3092914A1 (en) * 2018-03-05 2019-09-12 Solva, Llc Water-soluble phytocannabinoid formulations
US11397738B2 (en) * 2018-03-07 2022-07-26 Iguazio Systems Ltd. Stateless stream handling and resharding
WO2019194871A1 (en) * 2018-04-05 2019-10-10 Erbst Steven Robert Therapeutic elastic bandage for modulating the endocannabinoid system
CN112969452A (zh) 2018-04-09 2021-06-15 艾乐文特科学公司 用于治疗动物疼痛的大麻提取物
CN112752556A (zh) * 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
EP3793542A4 (en) * 2018-05-14 2022-03-30 Buzzelet Development And Technologies Ltd TERPENE-ENRICHED CANNABINOID COMPOSITIONS AND THEIR USES IN THE TREATMENT OF INFECTIOUS DISEASES
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020001770A1 (en) * 2018-06-28 2020-01-02 Symrise Ag Synthesis of (+)-cannabinoids and their therapeutic effects
US11013715B2 (en) 2018-07-19 2021-05-25 Vertosa, Inc. Nanoemulsion hydrophobic substances
US11504416B2 (en) 2018-09-04 2022-11-22 Paw Power, Inc. Formulation with cannabinoids
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
JP7500550B2 (ja) 2018-10-12 2024-06-17 ノバリック ゲーエムベーハー 乾性眼疾患の治療のための眼科用組成物
US20210361612A1 (en) * 2018-10-15 2021-11-25 Amnon Vardi Slow release cannabinoids and products thereof
CA3117910A1 (en) * 2018-11-08 2020-05-14 Gbs Global Biopharma, Inc. Therapeutic nanoparticles encapsulating terpenoids and/or cannabinoids
CA3119992A1 (en) * 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
KR20210114409A (ko) 2018-12-11 2021-09-23 디스럽션 랩스 인코퍼레이티드 치료제 전달용 조성물과 이의 이용 및 제조 방법
JP2022513442A (ja) 2018-12-11 2022-02-08 ナノファイバー ソリューションズ、エルエルシー 電界紡糸繊維を使用した慢性創傷の治療方法
US20200188298A1 (en) * 2018-12-14 2020-06-18 NuVessl, Inc. Method For Using Composition With Enhanced Passenger Molecule Loading
WO2020186246A1 (en) * 2019-03-13 2020-09-17 Ulagaraj Selvaraj Stabilized solid nanoparticle formulations of cannabinoids and cannabinoid analogs with reduced ostwald ripening for oral, inhalation, nasal and parenteral drug delivery
CA3040547C (en) * 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
WO2020263975A1 (en) * 2019-06-24 2020-12-30 Diverse Biotech, Inc. Beta-lactam-cannabinoid conjugate molecules
EP3989959A4 (en) * 2019-06-28 2023-05-03 Nexzol Pharma, Inc. TRANSDERMAL FORMULATIONS
US11717494B2 (en) * 2020-01-08 2023-08-08 Societe Des Produits Nestle S.A. Oral solid cannabinoid oil composition for treating gastrointestinal disorders
CN115087439A (zh) * 2020-02-21 2022-09-20 纳米纤维解决方案股份有限公司 具有药物的电纺结构及其制造和使用方法
US20230143752A1 (en) * 2020-03-05 2023-05-11 University Of Miami Cannabidiol nanodrug formulations and methods for use of the same
WO2021243468A1 (en) * 2020-06-04 2021-12-09 London Pharmaceuticals And Research Corporation Rigid cannabidiol analogues as potent modulators of cannabinoid receptors and uses thereof
US11524040B2 (en) 2020-08-24 2022-12-13 Charlotte's Web, Inc. Composition for the treatment of acne
US20220096369A1 (en) * 2020-09-25 2022-03-31 Irwin C. Jacobs Compositions comprising cannabinoids and methods of use thereof
EP4288105A1 (en) * 2021-02-04 2023-12-13 Ariel Scientific Innovations Ltd. Preparation of hyaluronic acid cbd conjugates
DK202170171A1 (en) 2021-04-13 2022-10-19 Cs Medica As Hair serum and supplement
CN117580584A (zh) * 2021-04-29 2024-02-20 禧尔公司 用于富集特定蛋白质子集的肽修饰纳米颗粒
WO2023086903A1 (en) * 2021-11-10 2023-05-19 Nano Pharmasolutions, Inc. Cannabidiol nanoparticle compositions
US11660348B1 (en) 2022-02-01 2023-05-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
US11883499B2 (en) 2022-02-01 2024-01-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
WO2023187842A2 (en) * 2022-04-02 2023-10-05 Akseera Pharma Corp. Augmentation of anti-viral and anti-cancer treatments by combinations of poly(i:c) and cannabidiol
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024742A (en) 1988-02-24 1991-06-18 Cedars-Sinai Medical Center Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US6113940A (en) 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
WO2002100325A2 (en) 2000-10-13 2002-12-19 Ligocyte Pharmaceuticals, Inc. Polyvalent nanoparticles
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
DE60228713D1 (de) 2001-07-18 2008-10-16 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
JP4851067B2 (ja) * 2004-01-28 2012-01-11 ホソカワミクロン株式会社 ナノ粒子含有組成物およびその製造方法
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
UA92498C2 (ru) * 2005-06-16 2010-11-10 Евро-Селтик С.А. Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
CA2657332A1 (en) * 2006-07-14 2008-01-17 Wine, Harvey Transdermal formulations of synthetic cannabinoids and nano colloidal silica
WO2008127459A1 (en) 2007-04-16 2008-10-23 Blum Richard S Pharmacological treatment of psoriasis
CN102245218B (zh) * 2008-12-19 2014-10-22 Sca卫生用品公司 包含超吸收聚合物和纤维素纳米纤丝的超吸收聚合物复合物

Also Published As

Publication number Publication date
JP2014520817A (ja) 2014-08-25
US20140302121A1 (en) 2014-10-09
US20130011484A1 (en) 2013-01-10
EP2729123A4 (en) 2014-08-20
EP2995302A1 (en) 2016-03-16
MX2014000141A (es) 2015-03-20
MX340962B (es) 2016-07-27
CA2840907C (en) 2018-09-11
CN103796637A (zh) 2014-05-14
US8758826B2 (en) 2014-06-24
EP2729123A2 (en) 2014-05-14
KR20140065387A (ko) 2014-05-29
WO2013006729A3 (en) 2014-05-08
WO2013006729A2 (en) 2013-01-10
EP2729123B8 (en) 2015-11-25
EP2729123B1 (en) 2015-10-14
CA2840907A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
DK2729123T3 (da) Cannabinoidreceptorbindende midler samt sammensætninger og fremgangsmåder
Qu et al. Advanced nanocarrier-and microneedle-based transdermal drug delivery strategies for skin diseases treatment
CN111848832B (zh) 含氟化合物修饰的阳离子聚合物作为药物载体的应用及制备方法
Das et al. Ethosomes as novel vesicular carrier: An overview of the principle, preparation and its applications
Wadhwa et al. New insights into quercetin nanoformulations for topical delivery
EP2548581A2 (en) A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
KR20130129953A (ko) 난용성 화합물의 용해도를 증가시키는 방법과 이와 같은 화합물의 제형을 제조하는 방법 및 사용하는 방법
US20160339042A1 (en) Topical lipolysis compositions and methods
CA3138630A1 (en) Cannabinoid stock transdermal formulations
JP2003524635A (ja) 活性作用物の局所デリバリー用キトサンバイオポリマー
JP2010530869A (ja) 過剰増殖性皮膚疾患の局所治療におけるヒアルロン酸のコンジュゲートの使用
Mohammadi et al. Bacterial cellulose-based composites as vehicles for dermal and transdermal drug delivery: a review
Yücel et al. Ethosomal (−)-epigallocatechin-3-gallate as a novel approach to enhance antioxidant, anti-collagenase and anti-elastase effects
Zhang et al. Dissolving microneedles based on polysaccharide for dermatological diseases therapy
Pozos-Nonato et al. Novel nanotechnological strategies for skin anti-aging
Ghosh et al. Recent advancements in nanocarrier based therapy against acne: The role of biosurfactants and status of patents
Kaur et al. Formulation strategies and therapeutic applications of shikonin and related derivatives
US20160045439A1 (en) Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same
Li et al. Fabrication of carboxymethyl cellulose/hyaluronic acid/polyvinylpyrrolidone composite pastes incorporation of minoxidil-loaded ferulic acid-derived lignin nanoparticles and valproic acid for treatment of androgenetic alopecia
Silvestrini et al. Advanced topical and transdermal drug delivery (TTDS) used in skin diseases and lesions of the aging
Bao et al. Ultrasound-Triggered On-Demand Insulin Release for Diabetes Mellitus Treatment
Alaimo et al. Gellan gum-based dermatological formulations
Mahajan et al. Tofacitinib in dermatology: a potential opportunity for topical applicability through novel drug-delivery systems
Khairnar et al. Recent Trends in Nanocarrier Formulations of Actives beyond Minoxidil and 5-α Reductase Inhibitors in Androgenetic alopecia Management: A Systematic Review
ul Hassan Design, Optimization and Characterization of Nalbuphine Polymeric Nanoparticles Loaded Patch for Transdermal Delivery